CymitQuimica logo

CAS 442201-24-3

:

Remogliflozin etabonate

Description:
Remogliflozin etabonate is a novel sodium-glucose co-transporter 2 (SGLT2) inhibitor primarily used in the management of type 2 diabetes mellitus. It functions by inhibiting the reabsorption of glucose in the kidneys, thereby promoting glucose excretion in urine and lowering blood glucose levels. The substance is characterized by its chemical structure, which includes a specific arrangement of carbon, hydrogen, oxygen, and nitrogen atoms, contributing to its pharmacological activity. Remogliflozin etabonate is typically administered orally and has been studied for its efficacy in improving glycemic control, as well as its potential cardiovascular benefits. Its safety profile is generally favorable, with common side effects including urinary tract infections and genital mycotic infections, which are associated with increased glucose in the urine. As with other SGLT2 inhibitors, it is important for patients to be monitored for potential adverse effects, particularly in those with renal impairment. Overall, Remogliflozin etabonate represents a significant advancement in diabetes treatment options.
Formula:C26H38N2O9
InChI:InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
InChI key:InChIKey=UAOCLDQAQNNEAX-ABMICEGHSA-N
SMILES:O(C=1C(CC2=CC=C(OC(C)C)C=C2)=C(C)N(C(C)C)N1)[C@@H]3O[C@H](COC(OCC)=O)[C@@H](O)[C@H](O)[C@H]3O
Synonyms:
  • Remogliflozin etabonate
  • β-D-Glucopyranoside, 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, 6-(ethyl carbonate)
  • BHV 091009
  • GSK 189075
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.